RESUMEN
OBJECTIVE: Pneumocystis pneumonia (PcP) is an opportunistic infection occurring in immunocompromised patients. Cushing's syndrome (CS) impairs the immune system, and several authors have reported PcP in patients with CS. The present study aimed to characterize PcP occurring in a CS context and its management in French tertiary centers, in order to highlight the similarities in clinical presentation and treatment according to whether prophylaxis is implemented or not. METHODS: This was a multicenter retrospective study conducted in several French University Hospitals and Cancer Centers. Patients with PcP and confirmed CS regardless of etiology were included. We excluded patients with other known causes of acquired immunodeficiency with increased risk of PcP. RESULTS: Twenty-five patients were included. CS etiology was neoplastic in 84.0% of cases. CS clinical presentation associated predominant catabolic signs (76.0%), hypokalemia (91.7%) and lymphopenia (89.5%). CS was intense in most patients, with mean plasma cortisol levels at diagnosis of 2.424±1.102nmol/L and urinary free cortisol>10× the upper limit of normal in 85.0%. In all patients, PcP onset followed introduction of cortisol blockers, at a median 5.5 days. Patients were treated with 1 to 3 cortisol blockers, mainly metyrapone (88%), which significatively lowered plasma cortisol levels to 667±541nmol/L at the onset of PcP (P<0.001). PcP occurred in 7 patients despite prophylaxis. Finally, 60.0% patients were admitted to intensive care, and 20.0% died of PcP. CONCLUSION: High mortality in patients with PcP implies that clinicians should be better informed about this rare infectious complication. Prophylaxis remains controversial, requiring comparative studies.
Asunto(s)
Síndrome de Cushing , Neumonía por Pneumocystis , Humanos , Síndrome de Cushing/complicaciones , Síndrome de Cushing/epidemiología , Síndrome de Cushing/diagnóstico , Estudios Retrospectivos , Neumonía por Pneumocystis/complicaciones , Neumonía por Pneumocystis/epidemiología , Hidrocortisona , Metirapona/uso terapéuticoRESUMEN
CONTEXT: Familial hypocalciuric hypercalcemia (FHH) is a genetically heterogeneous condition resembling primary hyperparathyroidism (PHPT) but not curable by surgery; FHH types 1, 2, and 3 are due to loss-of-function mutations of the CASR, GNA11, or AP2S1 genes, respectively. OBJECTIVE: This study aimed to compare the phenotypes of patients with genetically proven FHH types 1 or 3 or PHPT. DESIGN, SETTING, AND PATIENTS: This was a mutation analysis in a large cohort, a cross-sectional comparison of 52 patients with FHH type 1, 22 patients with FHH type 3, 60 with PHPT, and 24 normal adults. INTERVENTION: There were no interventions. MAIN OUTCOME MEASURES: Abnormalities of the CASR, GNA11, and AP2S1 genes, blood calcium, phosphate, and PTH concentrations, urinary calcium excretion were measured. RESULTS: In 133 families, we detected 101 mutations in the CASR gene, 68 of which were previously unknown, and in 19 families, the three recurrent AP2S1 mutations. No mutation was detected in the GNA11 gene. Patients with FHH type 3 had higher plasma calcium concentrations than patients with FHH type 1, despite having similar PTH concentrations and urinary calcium excretion. Renal tubular calcium reabsorption levels were higher in patients with FHH type 3 than in those with FHH type 1. Plasma calcium concentration was higher whereas PTH concentration and urinary calcium excretion were lower in FHH patients than in PHPT patients. In patients with FHH or PHPT, all data groups partially overlapped. CONCLUSION: In our population, AP2S1 mutations affect calcium homeostasis more severely than CASR mutations. Due to overlap, the risk of confusion between FHH and PHPT is high.
Asunto(s)
Complejo 2 de Proteína Adaptadora/genética , Subunidades sigma de Complejo de Proteína Adaptadora/genética , Subunidades alfa de la Proteína de Unión al GTP/genética , Hipercalcemia/congénito , Hiperparatiroidismo Primario/genética , Receptores Sensibles al Calcio/genética , Adulto , Calcio/sangre , Estudios Transversales , Análisis Mutacional de ADN , Femenino , Genotipo , Humanos , Hipercalcemia/sangre , Hipercalcemia/genética , Hiperparatiroidismo Primario/sangre , Masculino , Persona de Mediana Edad , Mutación , Hormona Paratiroidea/sangre , FenotipoRESUMEN
Hirsutism induced by hyperandrogenism can be associated with polycystic ovary syndrome, 21-hydroxylase (OH) deficiency or androgen-secreting tumors, including ovarian and adrenal tumors. Adrenal androgen-secreting tumors are frequently malignant. Adrenal oncocytomas represent rare causes of hyperandrogenism. The aim of the study was to investigate steroidogenic enzyme expression and steroid secretion in an androgen-secreting adrenal oncocytoma in a young woman presenting with hirsutism. Hyperandrogenism was diagnosed on the basis of elevated plasma Δ4-androstenedione and testosterone levels. Pelvic ultrasound was normal, CT scanning revealed a right adrenal mass. Androgens were assessed in adrenal and ovarian vein samples and proved a right adrenal origin. Adrenalectomy normalized androgen levels and the adrenal tumor was diagnosed as an oncocytoma. Real time-PCR, immunohistochemistry and cell culture studies were performed on tumor explants to investigate the steroid secretion profile. Among enzymes required for cortisol synthesis, 17α-OH and 3ß-hydroxysteroid dehydrogenase 2 (3ß-HSD2) were highly expressed whereas 21-OH and 11ß-OH were weakly produced at the mRNA and/or protein levels. Enzymes involved in testosterone production, 17ß-HSD5 and 17ß-HSD3, were also detected. ACTH receptor was present in the tissue. Cortisol, Δ4-androstenedione and testosterone secretions by cultured cells were increased by ACTH. These results provide the first demonstration, to our knowledge, of abnormal expression profile of steroidogenic enzymes in an adrenocortical oncocytoma. Our results also indicate that Δ4-androstenedione hypersecretion resulted from high 17α-OH and 3ß-HSD2 expression in combination with low expression of 21-OH and 11ß-OH. Testosterone production was ascribed to occurrence of 17ß-HSD5 and 17ß-HSD3. Finally, our results indicate that androgen secretion was stimulated by ACTH.
RESUMEN
BACKGROUND: Laminopathies, due to mutations in LMNA, encoding A type-lamins, can lead to premature ageing and/or lipodystrophic syndromes, showing that these diseases could have close physiopathological relationships. We show here that lipodystrophy and extreme insulin resistance can also reveal the adult progeria Werner syndrome linked to mutations in WRN, encoding a RecQ DNA helicase. METHODS: We analysed the clinical and biological features of two women, aged 32 and 36, referred for partial lipodystrophic syndrome which led to the molecular diagnosis of Werner syndrome. Cultured skin fibroblasts from one patient were studied. RESULTS: Two normal-weighted women presented with a partial lipodystrophic syndrome with hypertriglyceridemia and liver steatosis. One of them had also diabetes. Both patients showed a peculiar, striking lipodystrophic phenotype with subcutaneous lipoatrophy of the four limbs contrasting with truncal and abdominal fat accumulation. Their oral glucose tolerance tests showed extremely high levels of insulinemia, revealing major insulin resistance. Low serum levels of sex-hormone binding globulin and adiponectin suggested a post-receptor insulin signalling defect. Other clinical features included bilateral cataracts, greying hair and distal skin atrophy. We observed biallelic WRN null mutations in both women (p.Q748X homozygous, and compound heterozygous p.Q1257X/p.M1329fs). Their fertility was decreased, with preserved menstrual cycles and normal follicle-stimulating hormone levels ruling out premature ovarian failure. However undetectable anti-müllerian hormone and inhibin B indicated diminished follicular ovarian reserve. Insulin-resistance linked ovarian hyperandrogenism could also contribute to decreased fertility, and the two patients became pregnant after initiation of insulin-sensitizers (metformin). Both pregnancies were complicated by severe cervical incompetence, leading to the preterm birth of a healthy newborn in one case, but to a second trimester-abortion in the other. WRN-mutated fibroblasts showed oxidative stress, increased lamin B1 expression, nuclear dysmorphies and premature senescence. CONCLUSIONS: We show here for the first time that partial lipodystrophy with severe insulin resistance can reveal WRN-linked premature aging syndrome. Increased expression of lamin B1 with altered lamina architecture observed in WRN-mutated fibroblasts could contribute to premature cellular senescence. Primary alterations in DNA replication and/or repair should be considered as possible causes of lipodystrophic syndromes.
Asunto(s)
Exodesoxirribonucleasas/genética , Resistencia a la Insulina/genética , Lipodistrofia/complicaciones , Lipodistrofia/genética , Mutación , RecQ Helicasas/genética , Síndrome de Werner/complicaciones , Síndrome de Werner/genética , Adulto , Células Cultivadas , Senescencia Celular/genética , Femenino , Fibroblastos/metabolismo , Humanos , Recién Nacido , Lipodistrofia/fisiopatología , Embarazo , Piel/citología , Síndrome de Werner/diagnóstico , Helicasa del Síndrome de WernerRESUMEN
Progesterone-receptor modulators (PRMs) are progesterone-receptor ligands that can exert agonistic, antagonistic or mixed agonist-antagonist effects depending on the cellular context. The mechanisms of action of these compounds are still incompletely understood. PRMs already have several applications in women's health such as emergency contraception, pregnancy termination, management of early fetal demise and cervical maturation. The main indications that will be developed in the future include dysfunctional bleeding and preoperative treatment of uterine myomas. Other future indications may include estrogen-free contraception, treatment of endometriosis and prevention and treatment of breast cancer. However, the available data from mid- to long-term continuous administration studies has raised the issue of endometrial safety. For this reason, long-term applications of PRMs are currently postponed, although windows of treatment with a short course of progestin therapy, or even by a short interruption of treatment, could improve endometrial aspects if needed.
Asunto(s)
Antagonistas de Hormonas/farmacología , Progestinas/farmacología , Receptores de Progesterona/agonistas , Receptores de Progesterona/antagonistas & inhibidores , Útero/efectos de los fármacos , Animales , Anticonceptivos Sintéticos Orales/farmacología , Femenino , Humanos , Leiomioma/tratamiento farmacológico , Metrorragia/tratamiento farmacológico , Mifepristona/farmacología , Neoplasias Uterinas/tratamiento farmacológicoRESUMEN
Currently developed progesterone receptor modulators (PRMs) are steroid-derived compounds with mild or potent antiprogestin activity. PRMs may exert a contraceptive activity by different mechanisms such as blockade of ovulation and endometrial desynchronization. Their potential clinical applications are manifold and are very promising in major public health areas, including emergency contraception, long term oestrogen-free contraception (administered alone, or in association with a progestin-only pill to improve bleeding patterns), endometriosis and myoma treatment. The mechanisms of their anti-ovulatory effects and of the endometrial modifications elicited during long term PRM treatment are still not fully elucidated. In future clinical applications, PRMs will be administered orally, via intrauterine systems or vaginal rings.
Asunto(s)
Anticonceptivos Hormonales Orales/farmacología , Anticonceptivos Poscoito/farmacología , Receptores de Progesterona/efectos de los fármacos , Anticonceptivos Femeninos/farmacología , Anticonceptivos Sintéticos Orales/farmacología , Femenino , Humanos , Mifepristona/farmacología , Ovulación/efectos de los fármacos , Hemorragia Uterina/etiologíaRESUMEN
Progesterone antagonists belong to the family of selective progesterone receptor modulators. SPRMs already have several applications in women's health. Their main value lies in their effect on endometrium. For example, they can be used to reduce tumor volume and uterine bleeding before uterine myoma surgery. They are also being evaluated for the treatment of endometriosis, and for estrogen-free contraception.
Asunto(s)
Antagonistas de Hormonas/uso terapéutico , Receptores de Progesterona/efectos de los fármacos , Neoplasias de la Mama/tratamiento farmacológico , Endometriosis/tratamiento farmacológico , Femenino , Antagonistas de Hormonas/química , Humanos , Leiomioma/tratamiento farmacológico , Estructura Molecular , Neoplasias Uterinas/tratamiento farmacológicoRESUMEN
Menopause is a natural phenomenon consisting in follicles atresia and decrease in ovarian hormonal secretions. The mean age of menopause is 51 years. It is known that follicles atresia is partially explained by genetics factors. During this period, we observe hormonal variations. The most important of them are an elevation of FSH level, a decrease in estrogens. We also note a variation of androgens secretion. Hypo-oestrogenia induces various clinical symptoms. Some of them occur early in menopause (climateric syndrom), others occur later (osteoporosis, cardiovascular diseases).
Asunto(s)
Menopausia/fisiología , Edad de Inicio , Anciano , Envejecimiento/fisiología , Femenino , Hormonas Esteroides Gonadales/metabolismo , Humanos , Persona de Mediana Edad , Folículo Ovárico/fisiologíaRESUMEN
Postmenopausal age women have an increased risk of cardiovascular diseases, osteoporosis, and gynaecological cancers. A regular follow up is necessary to evaluate the interest of HRT, and for screening cardiovascular diseases and gynaecologic cancers. Patient counselling includes life style modifications, follow-up and regular evaluation of risk factors and potential benefit of HRT for each woman.